Nabla Bio

We use AI to design antibodies for intractable diseases

nabla.bio

HQ: Boston, MA, USA

1-10

Healthcare

Company research

Public company, workplace, funding, and market signals

Updated Jul 30, 2026

Overview

Nabla Bio is a Cambridge-based biotechnology company (founded in 2020, publicly launched in 2021) building JAM / JAM-2, a multimodal generative protein-design platform that combines AI with integrated wet-lab experimentation to design de novo antibodies and multispecific biologics for hard-to-drug targets, especially membrane proteins.

Primary product

JAM / JAM-2, a multimodal generative antibody design platform for de novo biologics design

Founded

2020

Headquarters

840 Memorial Dr, Riverside Technology Center, Cambridge, Massachusetts 02139, United States

Team size

11-50 employees

Work style

Onsite

Industry

Biotechnology

Sub-industry

AI drug discovery / antibody design

Offices

Cambridge, Massachusetts, United States (fully in-person; Riverside Technology Center)

Business model

pharma collaboration partnerships

platform-enabled drug discovery

internal licensing of designed biologics

Funding

Stage

Series A

Total raised

$37.5M

Latest round

Series A · May 2024

Latest amount

$26M

Series A

May 2024 · Radical Ventures

$26M

Seed VC

Dec 2021 · Khosla Ventures and Zetta Venture Partners

$11M

Grant

Mar 2021 · National Science Foundation

$256K

Seed

Sep 2020

$125K

Pre-Seed

Aug 2020 · Fifty Years

Corporate Round

May 2020

People & investors

Leadership

Surge Biswas

Co-founder & CEO

Frances Anastassacos

Co-founder & President

Rose Harrison

Chief Business Officer

George Church

Co-founder

Investors

Boom Capital Ventures

Cantos Ventures

Fifty Years

Khosla Ventures

National Science Foundation

Radical Ventures

Zetta Venture Partners

Work & culture

Data-driven, speed-oriented, rigor-focused, and highly collaborative; the company emphasizes in-person lab work, steep growth, and debating ideas with data rather than ego.

Work style

Onsite

Compensation

Not publicly disclosed; the careers page lists compensation as an FAQ but does not provide a public answer.

Product & market

Pricing

Primarily partnership-based and licensing-based; pricing terms are not publicly disclosed.

Differentiators

—De novo antibody and multispecific design from sequence/epitope context
—Integrated AI plus wet-lab experimentation
—Human-relevant measurement data used to train the platform
—Focus on difficult membrane targets such as GPCRs, ion channels, and transporters
—Drug-like affinity and developability designed in from the start
—High-throughput parallel testing and short design-to-test cycles

Technology

JAM (Joint Atomic Modeling)

JAM-2

Python

PyTorch

Pandas

NumPy

scikit-learn

Unix

AWS

GitHub

Docker

Kubernetes

SQL

React

multimodal generative modeling

human-relevant experimental measurements

large-scale wet-lab testing

Customers

AstraZeneca

Bristol Myers Squibb

Takeda

pharmaceutical companies

Competitors

Generate:Biomedicines

Absci

Xaira Therapeutics

Chai Discovery

Manifold Bio

Scale & contact

Estimated revenue

$1M-$10M

bd@nabla.bio 617-399-1300

Latest news

Nabla Bio announces AI antibody model update in JAM-2

Endpoints News · Nov 2025

Described JAM-2 as a major step up in drug-like de novo antibody design, with better success rates, developability, and GPCR results.

US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership

Reuters · Oct 2025

Reported a second multi-year Takeda collaboration, with double-digit-million upfront/research payments and potential success-based payments above $1B.

AI conjures up potential new antibody drugs in a matter of months

Science · May 2025

Covered Nabla's GPCR-targeting antibody candidates and its test-time scaling approach, including evidence of functional antibody activators.

Nabla Bio moves closer to AI-created antibodies

Endpoints News · Nov 2024

Reported Nabla's progress toward fully computationally designed antibodies and highlighted the company's GPCR-focused de novo antibody work.

Nabla Bio Secures $26M Series A Financing and Collaborations with AstraZeneca, Bristol Myers Squibb and Takeda for Generative Protein Design

Business Wire · May 2024

Announced a $26M Series A led by Radical Ventures and strategic collaborations with AstraZeneca, Bristol Myers Squibb, and Takeda worth more than $550M in upfront and milestone payments plus royalties.

Jobs and careers at Nabla Bio

19 jobs at Nabla Bio

AI/ML Software Engineer

On-site

Engineering

Paris office; Paris, France, France

2d ago

On-site

Full-time